Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapy

Fig. 3

Complete response rates to APF530 250 and 500 mg SC and palonosetron 0.25 mg IV. Graphs show complete response rates in breast cancer patients receiving 4 cycles of (a) moderately emetogenic chemotherapy or (b) highly emetogenic chemotherapy regimens

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us